Literature DB >> 18827575

Selenium and anticarcinogenesis: underlying mechanisms.

Matthew I Jackson1, Gerald F Combs.   

Abstract

PURPOSE OF REVIEW: To discuss recent research related to anticarcinogenic mechanisms of selenium action in light of the underlying chemical/biochemical functions of the selenium species, likely to be executors of those effects. RECENT
FINDINGS: Recent studies in a variety of model systems have increased the understanding of the anticarcinogenic mechanisms of selenium compounds. These include effects on gene expression, DNA damage and repair, signaling pathways, regulation of cell cycle and apoptosis, metastasis and angiogenesis. These effects would appear to be related to the production of reactive oxygen species produced by the redox cycling, modification of protein-thiols and methionine mimicry. Three principle selenium metabolites appear to execute these effects: hydrogen selenide, methylselenol and selenomethionine. The fact that various selenium compounds can be metabolized to one or more of these species but differ in anticarcinogenic activity indicates competing pathways of their metabolic and chemical/biochemical disposition. Increasing knowledge of selenoprotein polymorphisms has shown that at least some are related to cancer risk and may affect carcinogenesis indirectly by influencing selenium metabolism.
SUMMARY: The anticarcinogenic effects of selenium compounds constitute intermediate mechanisms with several underlying chemical/biochemical mechanisms such as redox cycling, alteration of protein-thiol redox status and methionine mimicry.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18827575     DOI: 10.1097/MCO.0b013e3283139674

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  59 in total

Review 1.  Selenium for preventing cancer.

Authors:  Marco Vinceti; Gabriele Dennert; Catherine M Crespi; Marcel Zwahlen; Maree Brinkman; Maurice P A Zeegers; Markus Horneber; Roberto D'Amico; Cinzia Del Giovane
Journal:  Cochrane Database Syst Rev       Date:  2014-03-30

2.  Selenomethionine and alpha-tocopherol do not inhibit prostate carcinogenesis in the testosterone plus estradiol-treated NBL rat model.

Authors:  Nur Ozten; Lori Horton; Salamia Lasano; Maarten C Bosland
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-23

3.  The effect of selenium enrichment on baker's yeast proteome.

Authors:  Karam El-Bayoumy; Arunangshu Das; Stephen Russell; Steven Wolfe; Rick Jordan; Kutralanathan Renganathan; Thomas P Loughran; Richard Somiari
Journal:  J Proteomics       Date:  2011-10-29       Impact factor: 4.044

4.  The selenium analog of the chemopreventive compound S,S'-(1,4-phenylenebis[1,2-ethanediyl])bisisothiourea is a remarkable inducer of apoptosis and inhibitor of cell growth in human non-small cell lung cancer.

Authors:  Arunangshu Das; James Bortner; Dhimant Desai; Shantu Amin; Karam El-Bayoumy
Journal:  Chem Biol Interact       Date:  2009-03-20       Impact factor: 5.192

Review 5.  Selenoproteins that function in cancer prevention and promotion.

Authors:  Dolph L Hatfield; Min-Hyuk Yoo; Bradley A Carlson; Vadim N Gladyshev
Journal:  Biochim Biophys Acta       Date:  2009-03-09

6.  Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.

Authors:  Christopher H Miller; Shahista Nisa; Sandi Dempsey; Cameron Jack; Ronan O'Toole
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

7.  L-selenomethionine does not protect against testosterone plus 17β-estradiol-induced oxidative stress and preneoplastic lesions in the prostate of NBL rats.

Authors:  Nur Özten; Michael Schlicht; Alan M Diamond; Maarten C Bosland
Journal:  Nutr Cancer       Date:  2014-04-28       Impact factor: 2.900

8.  The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology.

Authors:  Dolph L Hatfield; Vadim N Gladyshev
Journal:  Mol Interv       Date:  2009-02

9.  Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound.

Authors:  Youcef M Rustum; Károly Tóth; Mukund Seshadri; Arindam Sen; Farukh A Durrani; Emily Stott; Carl D Morrison; Shousong Cao; Arup Bhattacharya
Journal:  J Oncol       Date:  2010-04-27       Impact factor: 4.375

10.  The glutaredoxin GLRX-21 functions to prevent selenium-induced oxidative stress in Caenorhabditis elegans.

Authors:  Kathleen L Morgan; Annette O Estevez; Catherine L Mueller; Briseida Cacho-Valadez; Antonio Miranda-Vizuete; Nathaniel J Szewczyk; Miguel Estevez
Journal:  Toxicol Sci       Date:  2010-09-10       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.